We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mylan (MYL) Launches Generic Version of Lilly's Adcirca
Read MoreHide Full Article
Mylan N.V. announced that it has launched tadalafil tablets — the first generic version of the reference branded drug, Eli Lilly and Company's (LLY - Free Report) Adcirca.
Along with the final approval from the FDA for its Abbreviated New Drug Application for the generic version of Adcirca, Mylan was awarded 180 days of marketing exclusivity for this product.
Adcirca is indicated for the treatment of pulmonary arterial hypertension to improve exercise ability.
The addition of generic Adcirca tablets strengthened Mylan’s cardiovascular portfolio.
New generic approvals should boost Mylan’s generic business in the United States. Mylan has 192 ANDAs pending FDA approval, representing approximately $88.3 billion in annual brand sales, as per IQVIA. Among these, 44 of the pending ANDAs are potential first-to-file opportunities, representing $44.9 billion in annual brand sales for the 12 months ending Dec 31, 2017, according to IQVIA.
Last month, Mylan had announced that it launched the generic version of Novartis’ (NVS - Free Report) Exelon patch, which is indicated for the treatment of dementia associated with mild, moderate and severe Alzheimer's disease and the treatment of mild to moderate dementia associated with Parkinson's disease.
However, the generic business in the United States continues to experience pricing and competitive pressure. The competitive pressure for EpiPen has increased further along with supply issues. The company earlier suffered a setback when the FDA refused to approved its Abbreviated New Drug Application for the generic version of GlaxoSmithKline’s (GSK - Free Report) asthma drug, Advair Diskus.
Mylan’s second-quarter results were dismal as challenges in North America persist prompting the management to evaluate strategic alternatives. Mylan lowered its outlook as a result of the change in expected complex product launch, utilization assumptions, resizing of product opportunities in the United States, and the negative impact on operations of the restructuring and remediation program in Morgantown. While the biosimilar business continues to gain traction buoyed by new approvals, these new approvals might not be enough to combat the persistent decline in North America.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Mylan (MYL) Launches Generic Version of Lilly's Adcirca
Mylan N.V. announced that it has launched tadalafil tablets — the first generic version of the reference branded drug, Eli Lilly and Company's (LLY - Free Report) Adcirca.
Along with the final approval from the FDA for its Abbreviated New Drug Application for the generic version of Adcirca, Mylan was awarded 180 days of marketing exclusivity for this product.
Adcirca is indicated for the treatment of pulmonary arterial hypertension to improve exercise ability.
The addition of generic Adcirca tablets strengthened Mylan’s cardiovascular portfolio.
New generic approvals should boost Mylan’s generic business in the United States. Mylan has 192 ANDAs pending FDA approval, representing approximately $88.3 billion in annual brand sales, as per IQVIA. Among these, 44 of the pending ANDAs are potential first-to-file opportunities, representing $44.9 billion in annual brand sales for the 12 months ending Dec 31, 2017, according to IQVIA.
Last month, Mylan had announced that it launched the generic version of Novartis’ (NVS - Free Report) Exelon patch, which is indicated for the treatment of dementia associated with mild, moderate and severe Alzheimer's disease and the treatment of mild to moderate dementia associated with Parkinson's disease.
However, the generic business in the United States continues to experience pricing and competitive pressure. The competitive pressure for EpiPen has increased further along with supply issues. The company earlier suffered a setback when the FDA refused to approved its Abbreviated New Drug Application for the generic version of GlaxoSmithKline’s (GSK - Free Report) asthma drug, Advair Diskus.
Mylan N.V. Price, Consensus and EPS Surprise
Mylan N.V. Price, Consensus and EPS Surprise | Mylan N.V. Quote
Mylan’s second-quarter results were dismal as challenges in North America persist prompting the management to evaluate strategic alternatives. Mylan lowered its outlook as a result of the change in expected complex product launch, utilization assumptions, resizing of product opportunities in the United States, and the negative impact on operations of the restructuring and remediation program in Morgantown. While the biosimilar business continues to gain traction buoyed by new approvals, these new approvals might not be enough to combat the persistent decline in North America.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>